Clinical Trials Logo

Filter by:
NCT ID: NCT05873257 Completed - Venous Leg Ulcer Clinical Trials

Investigation of the Clinical Performance of Biatain Fiber Ag on Venous Leg Ulcers

Start date: July 31, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to test a new gelling fiber wound dressing with silver on patients with a venous leg ulcer Participants will be asked to wear the test dressing in a four weeks period (+/- 2 days) consisting of 6 study visits, and will have the dressing changed once pr. week at the research facility. The wound will be cleaned, assessed and photos will be uploaded to a digital software system.

NCT ID: NCT05872698 Recruiting - Portal Hypertension Clinical Trials

Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial.

BOPPP
Start date: June 1, 2019
Phase: Phase 4
Study type: Interventional

Research has proven that large varices can be treated with beta-blockers (a type of anti-hypertensive medication) to reduce the pressure in the veins. The management of small varices is still uncertain. This study aims to discover if beta blockers can be used in this setting. We hypothesize that beta blockers will reduce the risk of bleeding from small varices from 20% to 10% over a period of 3 years, resulting in significant cost savings to the NHS from better patient outcomes.

NCT ID: NCT05872022 Enrolling by invitation - Obesity Clinical Trials

A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy

Start date: July 5, 2023
Phase:
Study type: Observational

This is an observational, prospective Wegovy (semaglutide 2.4 milligram [mg]) Pregnancy Registry Study. The aim of this study is to compare the maternal, foetal, and infant outcomes of pregnant women who are exposed to Wegovy during pregnancy for the treatment of obesity or overweight with at least one weight-related comorbid condition with outcomes in an internal comparison cohort of pregnant women with obesity or overweight with at least one weight related comorbid condition at conception and who are not exposed to Wegovy or other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) during pregnancy. Infant outcomes will be assessed throughout the infant's first year of life, with active data collection by the registry occurring at 4 and 12 months after delivery.

NCT ID: NCT05871996 Recruiting - Cancer Clinical Trials

Palliative Care and Oncology Survey on Terminology

POST
Start date: October 3, 2023
Phase:
Study type: Observational

The term '"cancer survivors" is widely used but has different definitions. One definition describes "cancer survivors" as individuals from the time of diagnosis throughout their lives, which includes people living with cancer and people free of cancer. The views of some groups included in this definition of "cancer survivors" have rarely been assessed, including those with cancer on anticancer treatment and those known to palliative care. How they view these terms could have important implications for how they receive care services. This is an international multi-centre observational study. It aims to recruit 3830 patients internationally across Australia, Canada, Ireland, the United Kingdom, and the United States of America. Participants known to cancer and/or palliative care hospital or hospice services as inpatients, outpatients or community patients will be asked to complete a survey during a one-off visit which should last under 30 minutes. The survey asks a series of questions to determine the perceptions of patients know to cancer and palliative care services about the terminologies used to describe them.

NCT ID: NCT05870540 Recruiting - Clinical trials for Treatment Resistant Depression

BPL-003 Efficacy and Safety in Treatment Resistant Depression

Start date: September 14, 2023
Phase: Phase 2
Study type: Interventional

This is a Phase 2 study randomized, quadruple masked, multi-center study designed to investigate the efficacy and safety of a single dose of BPL-003 combined with psychological support in patients with treatment resistant depression (TRD).

NCT ID: NCT05870501 Recruiting - Bipolar Disorder Clinical Trials

Synaptic Imaging and Network Activity in Treatment Resistant Depression

SIGNATURE
Start date: October 20, 2021
Phase: N/A
Study type: Interventional

The main aim of this research is to explore the effects that ketamine has on the functional connectivity of the brain in participants with treatment resistant depression (TRD). This study will investigate the relationship between these changes and response to treatment as measured by clinical scales, as well as examining drug induced changes in reward and emotion based brain activity, structural connectivity, cerebral blood flow, cognition, metabolism and blood markers of brain plasticity.

NCT ID: NCT05870332 Recruiting - Colo-rectal Cancer Clinical Trials

Nationwide Study of Artificial Intelligence in Adenoma Detection for Colonoscopy

NAIAD
Start date: October 16, 2023
Phase:
Study type: Observational

The goal of this trial is to determine whether use of a Computer Assisted Detection (CADe) programme leads to an increase in ADR for either units or individual colonoscopists, independent of setting or expertise

NCT ID: NCT05870228 Recruiting - Insomnia Clinical Trials

Investigating a Sleep Intervention for Adolescents Attending Mental Health Services

Start date: October 13, 2023
Phase: N/A
Study type: Interventional

The overall objectives of the study are to: 1. To assess the feasibility of delivering the Strathclyde Sleep Intervention to adolescents with co-morbid insomnia and mental health attending a mental health services The following feasibility benchmarks will be assessed: recruitment and retention, participant attendance, staff training, intervention fidelity and participant adherence. 2. To examine participant acceptability. The researchers will conduct qualitative interviews with the participants and delivery staff to examine the acceptability of the programme. 3. To investigate the preliminary effectiveness by assessing the following: sleep parameters, insomnia symptoms, Circadian phase preference (baseline only) and mental health symptoms. Data will be collected at baseline, post-intervention and 3 month follow-up.

NCT ID: NCT05870150 Recruiting - Gastroenteritis Clinical Trials

Challenge Non-Typhoidal Salmonella (CHANTS) Study

CHANTS
Start date: August 31, 2023
Phase: N/A
Study type: Interventional

This protocol describes the challenge non-typhoidal Salmonella (CHANTS) study. This is a first-in-human phase 1, double-blinded, randomised, dose-escalation human infection study, conducted in healthy volunteers aged 18 to 50 years. The primary objective of the study is to perform a dose escalation with two strains (ST19 or ST313) to determine the infectious dose required for 60-75% of volunteers to develop Salmonellosis using a composite diagnostic criterion. The secondary objectives of the study are to describe and compare the clinical and laboratory features following controlled human infection. It is hoped that the successful establishment of an NTS human challenge model can be used in the future to test candidate vaccines for NTS disease.

NCT ID: NCT05870137 Completed - Emergency Medicine Clinical Trials

Assessing Mixed Reality for Emergency Medical Care Delivery in a Simulated Environment

Start date: September 17, 2021
Phase: N/A
Study type: Interventional

This study assessed the feasibility and effectiveness of using Mixed Reality (MR) through the use of HoloLens2TM technology to enhance emergency clinical care delivery in a simulated environment. This was achieved by inviting 22 resident grade doctors to complete two scenarios. Each scenario was supported either by standard care methods or Mixed reality. The participants were randomised to at the start of the scenarios to determine which support they would receive first. The main outcome was to see if there was difference in error rates. This was assessed using the ICECAP multidimensional error capture tool. Secondary outcomes included teamwork, scenario completion, stress/cognitive load, and Mixed reality device user acceptability.